1. Peculiar immunophenotypic signature in MIS‐C‐affected children
- Author
-
Francesco Licciardi, Marco Denina, Marta Dellepiane, Letizia Baldini, Enrico Felici, Carlotta Covizzi, Emanuela Ricotti, Marisa Zoppo, Davide Montin, and Federica Mignone
- Subjects
Child ,Humans ,Immunophenotyping ,SARS-CoV-2 ,COVID-19 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Systemic inflammation ,Virus ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,hemic and lymphatic diseases ,Medicine ,Immunology and Allergy ,030212 general & internal medicine ,Pediatrics, Perinatology, and Child Health ,skin and connective tissue diseases ,Clinical syndrome ,business.industry ,fungi ,body regions ,Specific antibody ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,medicine.symptom ,business - Abstract
Since April 2020, an increasing number of authors have reported a new clinical syndrome related to SARS-COV2 infection in children, characterized by rapidly progressive systemic inflammation with multiorgan dysfunction. This syndrome has been addressed with many names since its description such as Multisystem Inflammatory Syndrome in children (MIS-C), Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-ST), and SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome (SCiKH).1-3 The pathogenesis of MIS-C is still unknown, even if the positivity of a nasopharyngeal RT-PCR assay for the SARS-COV2 and/or of specific antibody testing in most patients suggests that this syndrome develops while the immune system is activated against the SARS-COV2 virus.
- Published
- 2021
- Full Text
- View/download PDF